首页> 美国卫生研究院文献>Analytical Cellular Pathology : the Journal of the European Society for Analytical Cellular Pathology >Immunohistochemical Expression of CXCR4 on Breast Cancer and Its Clinical Significance
【2h】

Immunohistochemical Expression of CXCR4 on Breast Cancer and Its Clinical Significance

机译:CXCR4在乳腺癌中的免疫组织化学表达及其临床意义

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Many tumor cells express chemokines and chemokine receptors, and, for this reason, these molecules can affect the tumor progression. It is known that breast cancer is a complex and heterogeneous neoplasia comprising distinct diseases, histological characteristics, and clinical outcomes. The most studied role for CXCL12 chemokine and its receptor CXCR4 in breast cancer pathogenesis is the metastasis event, although several reports have demonstrated its involvement in other processes, such as angiogenesis and tumor growth. It has been found that CXCR4 is required for breast cancer cell migration to other sites such as lung, bone, and lymph nodes, which express high levels of CXCL12 chemokine. Therefore, CXCR4 is being considered a prognostic marker in breast cancer. Within this context, this review summarizes established studies involving expression of CXCR4 on breast cancer, focusing on its clinical significance.
机译:许多肿瘤细胞表达趋化因子和趋化因子受体,因此,这些分子会影响肿瘤的进展。众所周知,乳腺癌是一种复杂而异质的肿瘤,包括不同的疾病,组织学特征和临床结果。 CXCL12趋化因子及其受体CXCR4在乳腺癌发病机理中研究最多的作用是转移事件,尽管有几篇报道表明它参与了其他过程,例如血管生成和肿瘤生长。已经发现,乳腺癌细胞向表达高水平CXCL12趋化因子的其他部位如肺,骨和淋巴结迁移需要CXCR4。因此,CXCR4被认为是乳腺癌的预后指标。在此背景下,本综述总结了涉及CXCR4在乳腺癌上表达的既定研究,重点是其临床意义。

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号